Concepedia

Marco L. Lolli

ML

45

Publications

1.5K

Citations

25

H-Index

1993

Active since

Affiliations

University of Turin(Current)

Mario Negri Institute for Pharmacological Research

Lund University

University of Gothenburg

University of Copenhagen

Marco L. Lolli is an author at University of Turin specializing in pharmacology, natural sciences, and medicine.

ORCID

Top concepts

Publications per year

1993–2022

45

Publications

45

A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action

Elena Campaner, Alessandra Rustighi, Alessandro Zannini et al. · Nature Communications · 2017 · 142 citations · Full text

Antiinflammatory, Gastrosparing, and Antiplatelet Properties of New NO-Donor Esters of Aspirin

Clara Cena, Marco L. Lolli, Loretta Lazzarato et al. · Journal of Medicinal Chemistry · 2003 · 98 citations

A New Class of Ibuprofen Derivatives with Reduced Gastrotoxicity

Marco L. Lolli, Clara Cena, Claudio Medana et al. · Journal of Medicinal Chemistry · 2001 · 73 citations

, , +14

Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors

Stefano Sainas, Agnese Chiara Pippione, Elisa Lupino et al. · Journal of Medicinal Chemistry · 2018 · 68 citations · Full text

MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells

Cristian Taccioli, Giovanni Sorrentino, Alessandro Zannini et al. · Oncotarget · 2015 · 62 citations · Full text

Rows per page

1–5 of 45